Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update
August 8, 2019HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019.
“We’ve made significant progress on our pipeline in the last few months,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “Most notably, we completed enrollment in our first two poziotinib cohorts in the ZENITH20 study and expect to see results from cohort 1 in the fourth quarter. Based on strong science, we’ve expanded the poziotinib development program to include additional areas of high unmet medical need in lung cancer. We also had a productive meeting with the FDA and expect to submit the ROLONTIS BLA in the fourth quarter.”
Pipeline Overview:
Poziotinib, an irreversible tyrosine kinase inhibitor targeting EGFR and HER2 mutations:
-
The cornerstone poziotinb ZENITH20 trial currently consists of seven cohorts of patients with non-small cell lung cancer (NSCLC).
-
Cohorts Fully Enrolled
- Cohort 1: Previously treated patients with EGFR exon 20 insertion mutation; topline results expected in the fourth quarter 2019
- Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation; topline results expected in mid-2020
-
Cohorts Currently Enrolling
- Cohort 3: Treatment naïve patients with EGFR exon 20 insertion mutation
- Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutation
- Cohort 5: Previously treated or treatment naïve patients with EGFR or HER2 exon 20 insertion mutation
- Cohort 6: Previously treated first-line osimertinib patients with acquired EGFR mutations
- Cohort 7: Previously treated patients with atypical EGFR or HER2 mutation
-
Cohorts Fully Enrolled
- Spectrum expects to initiate a basket study in H2 2019.
ROLONTIS® (eflapegrastim), a novel long-acting GCSF:
-
Integrated data from both Phase 3 ROLONTIS clinical trials with 643 patients were presented in a poster session at American Society of Clinical Oncology 2019 annual meeting.
- The analysis found that integrated efficacy and safety data from the two identically designed Phase 3 trials – ADVANCE and RECOVER – were consistent with results from the individual trials, demonstrating that ROLONTIS was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of treatment.
- Spectrum met with the FDA and expects to submit the ROLONTIS BLA in the fourth quarter of 2019.
Business Development
-
In May 2019, Spectrum completed an asset purchase and license agreement with ImmunGene, Inc., a privately held biotechnology company.
- The deal includes an exclusive license for the intellectual property related to the FIT antibody-interferon fusion technology drug delivery platform and two innovative early-stage drug candidates derived from the platform.
- Originally developed by scientists at UCLA, the FIT platform fuses interferon with a monoclonal antibody providing a mechanism for targeting many different tumor antigens and has the potential for broad application in oncology.
Three-Month Period Ended June 30, 2019 (All numbers are from Continuing Operations and are approximate)
GAAP Results
Spectrum recorded a loss of $28.8 million, or a loss of $0.26 per basic and diluted share, in the three-month period ended June 30, 2019, compared to income of $14.9 million, or $0.15 income per basic share and $0.14 per diluted share, in the comparable period in 2018. Total research and development expenses were $17.0 million in the quarter, as compared to $16.6 million in the same period in 2018. Selling, general and administrative expenses were $17.2 million in the quarter, compared to $16.4 million in the same period in 2018.
The company ended the quarter with cash, cash equivalents, restricted cash, and marketable securities of $282 million.
Non-GAAP Results
Spectrum recorded a non-GAAP loss of $25.2 million, or a non-GAAP loss of $0.23 per basic and diluted share, in the three-month period ended June 30, 2019, compared to a non-GAAP loss of $28.8 million, or a non-GAAP loss of $0.28 per basic and diluted share, in the comparable period in 2018. Non-GAAP research and development expenses were $13.2 million, as compared to $15.4 million in the same period of 2018. Non-GAAP selling, general and administrative expenses were $13.7 million, as compared to $13.8 million in the same period in 2018.
Conference Call:
Thursday, August 8, 2019 @ 4:30 p.m. Eastern/1:30 p.m. Pacific
Domestic: (877) 837-3910, Conference ID# 5378656
International: (973) 796-5077, Conference ID# 5378656
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals’ website: http://investor.sppirx.com/events-and-presentations on August 8, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. More information on Spectrum is available at www.sppirx.com.
Notice Regarding Forward-looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These forward-looking statements relate to a variety of matters, including, without limitation, statements that relate to Spectrum’s business and its future, the Company’s ability to execute its long-term strategy, the timing of the BLA filing for ROLONTIS, the timing of the topline results from the poziotinib EGFR previously treated and HER2 previously treated non-small cell lung cancer cohort in the ZENITH20 trial, the potential for the two poziotinib cohorts to support an NDA filing with the FDA, the potential clinical applications for the FIT therapies, its potential for treating both solid and hematologic malignancies, the ability of the FIT therapies to meet currently unaddressed medical needs and the size of potential markets, the future potential of Spectrum’s existing drug pipeline, and any other statements that are not purely statements of historical fact. These forward-looking statements are based on management’s current beliefs, expectations and assumptions and are subject to significant risks and uncertainties. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Spectrum undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Spectrum believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements, including, without limitation, the uncertainties inherent in new product development, including clinical trial results and additional analysis of existing clinical data, the possibility that Spectrum’s applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that Spectrum’s existing and new drug candidates, including poziotinib, ROLONTIS and the FIT therapies, may not be more effective, safer or more cost efficient than competing drugs, and Spectrum’s dependence on third parties for clinical trials, manufacturing and quality control. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Spectrum in general, see the risk disclosures in the Annual Report on Form 10-K of Spectrum for the year ended December 31, 2018, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Spectrum.
SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals’ logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
© 2019 Spectrum Pharmaceuticals, Inc. All Rights Reserved
|
SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited) |
|||||||||||||||
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||
|
Revenues (Note 1(b)) |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
Operating costs and expenses: |
|
|
|
|
|
|
|
||||||||
|
Selling, general and administrative |
17,230 |
|
|
16,391 |
|
|
33,182 |
|
|
33,007 |
|
||||
|
Research and development |
16,982 |
|
|
16,595 |
|
|
38,868 |
|
|
29,960 |
|
||||
|
Total operating costs and expenses |
34,212 |
|
|
32,986 |
|
|
72,050 |
|
|
62,967 |
|
||||
|
Loss from continuing operations |
(34,212 |
) |
|
(32,986 |
) |
|
(72,050 |
) |
|
(62,967 |
) |
||||
|
Other income (expense): |
|
|
|
|
|
|
|
||||||||
|
Interest income (expense), net |
1,495 |
|
|
(242 |
) |
|
2,556 |
|
|
(473 |
) |
||||
|
Other income (expense), net |
3,722 |
|
|
48,492 |
|
|
(7,563 |
) |
|
58,463 |
|
||||
|
Total other income (expense) |
5,217 |
|
|
48,250 |
|
|
(5,007 |
) |
|
57,990 |
|
||||
|
(Loss) income from continuing operations before income taxes |
(28,995 |
) |
|
15,264 |
|
|
(77,057 |
) |
|
(4,977 |
) |
||||
|
Benefit (provision) for income taxes from continuing operations |
212 |
|
|
(370 |
) |
|
8,454 |
|
|
698 |
|
||||
|
(Loss) income from continuing operations |
$ |
(28,783 |
) |
|
$ |
14,894 |
|
|
$ |
(68,603 |
) |
|
$ |
(4,279 |
) |
|
Income (loss) from discontinued operations, net of income taxes |
388 |
|
|
(1,150 |
) |
|
21,053 |
|
|
2,205 |
|
||||
|
Net (loss) income |
$ |
(28,395 |
) |
|
$ |
13,744 |
|
|
$ |
(47,550 |
) |
|
$ |
(2,074 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Basic (loss) income per share: |
|
|
|
|
|
|
|
||||||||
|
(Loss) income per common share from continuing operations |
$ |
(0.26 |
) |
|
$ |
0.15 |
|
|
$ |
(0.63 |
) |
|
$ |
(0.04 |
) |
|
Income (loss) per common share from discontinued operations |
— |
|
|
(0.01 |
) |
|
0.19 |
|
|
0.02 |
|
||||
|
Net (loss) income per common share |
$ |
(0.26 |
) |
|
$ |
0.14 |
|
|
$ |
(0.44 |
) |
|
$ |
(0.02 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted (loss) income per share: |
|
|
|
|
|
|
|
||||||||
|
(Loss) income per common share from continuing operations |
$ |
(0.26 |
) |
|
$ |
0.14 |
|
|
$ |
(0.63 |
) |
|
$ |
(0.04 |
) |
|
Income (loss) per common share from discontinued operations |
— |
|
|
(0.01 |
) |
|
0.19 |
|
|
0.02 |
|
||||
|
Net (loss) income per common share |
$ |
(0.26 |
) |
|
$ |
0.13 |
|
|
$ |
(0.44 |
) |
|
$ |
(0.02 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Weighted average shares outstanding: |
|
|
|
|
|
|
|
||||||||
|
Basic |
110,345,135 |
|
|
102,597,059 |
|
|
109,744,405 |
|
|
101,747,416 |
|
||||
|
Diluted |
110,345,135 |
|
|
112,617,150 |
|
|
109,744,405 |
|
|
101,747,416 |
|
||||
|
SPECTRUM PHARMACEUTICALS, INC. Income from Discontinued Operations, net of Income Taxes (In thousands) (Unaudited) |
||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||
|
Product sales, net*** |
|
$ |
(1,245 |
) |
|
$ |
23,753 |
|
|
$ |
12,938 |
|
|
$ |
51,863 |
|
|
License fees and service revenue |
|
— |
|
|
415 |
|
|
290 |
|
|
2,799 |
|
||||
|
Total revenues |
|
$ |
(1,245 |
) |
|
$ |
24,168 |
|
|
$ |
13,228 |
|
|
$ |
54,662 |
|
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
||||||||
|
Cost of sales (excluding amortization of intangible assets) |
|
433 |
|
|
6,606 |
|
|
3,601 |
|
|
13,420 |
|
||||
|
Selling, general and administrative |
|
(61 |
) |
|
7,060 |
|
|
5,890 |
|
|
14,549 |
|
||||
|
Research and development |
|
255 |
|
|
4,893 |
|
|
2,791 |
|
|
9,422 |
|
||||
|
Amortization of intangible assets |
|
— |
|
|
6,934 |
|
|
1,248 |
|
|
13,880 |
|
||||
|
Restructuring – employee severance**** |
|
(2,439 |
) |
|
— |
|
|
3,858 |
|
|
— |
|
||||
|
Total operating costs and expenses |
|
$ |
(1,812 |
) |
|
$ |
25,493 |
|
|
$ |
17,388 |
|
|
$ |
51,271 |
|
|
Income (loss) from discontinued operations |
|
$ |
567 |
|
|
$ |
(1,325 |
) |
|
$ |
(4,160 |
) |
|
$ |
3,391 |
|
|
Other (expense) income: |
|
|
|
|
|
|
|
|
||||||||
|
Change in fair value of contingent consideration |
|
— |
|
|
(192 |
) |
|
(1,478 |
) |
|
(483 |
) |
||||
|
Gain on sale of Commercial Product Portfolio* |
|
— |
|
|
— |
|
|
33,644 |
|
|
— |
|
||||
|
Total other (expense) income |
|
$ |
— |
|
|
$ |
(192 |
) |
|
$ |
32,166 |
|
|
$ |
(483 |
) |
|
Income (loss) from discontinued operations before income taxes |
|
567 |
|
|
(1,517 |
) |
|
28,006 |
|
|
2,908 |
|
||||
|
(Provision) benefit for income taxes from discontinued operations** |
|
(179 |
) |
|
367 |
|
|
(6,953 |
) |
|
(703 |
) |
||||
|
Income (loss) from discontinued operations, net of income taxes |
|
$ |
388 |
|
|
$ |
(1,150 |
) |
|
$ |
21,053 |
|
|
$ |
2,205 |
|
*This pre-tax gain on sale represents the $158.8 million proceeds from the Commercial Product Portfolio Transaction less our $121.2 book value of transferred net assets (inclusive of assumed liabilities) to Acrotech on the March 1, 2019 closing date, and after legal and banker transaction expenses for the three months ended March 31, 2019 that aggregated $3.9 million.
**This income tax provision (benefit) represents an allocation of taxes as required under the intraperiod allocation guidance. Due to our aggregate net operating loss-carryforwards, no federal or state income tax payments are expected to be made relating to our current year activity, inclusive of our gain on sale of the Commercial Product Portfolio.
***The “Product sales, net” is inclusive of our commercial product sales for January and February 2019, as well as recognized EVOMELA product sales during the second quarter of 2019 to a single customer under an active contract that was not yet assumed by Acrotech. The negative revenue value reflects actual government chargeback claims received during the three months ended June 30, 2019 that were in excess of current period revenue for this interim EVOMELA supply arrangement and our then-existing allowance for government chargebacks.
****The “Restructuring – employee severance” negative value in the second quarter of 2019 reflects a current period reclassification to continuing operations “selling, general and administrative” and “research and development” expenses. This $2.4 million amount was previously included within “income (loss) from discontinued operations, net of income taxes” in the first quarter of 2019.
|
SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets (In thousands, expect per share and par value amounts) (Unaudited) |
|||||||
|
|
June 30, |
|
December 31, |
||||
|
ASSETS |
|
|
|
||||
|
Current assets: |
|
|
|
||||
|
Cash and cash equivalents |
$ |
118,251 |
|
|
$ |
157,480 |
|
|
Restricted cash |
4,020 |
|
|
— |
|
||
|
Marketable securities |
160,134 |
|
|
46,508 |
|
||
|
Accounts receivable, net of allowance for doubtful accounts of $67 and $67, respectively |
2,542 |
|
|
29,873 |
|
||
|
Other receivables |
10,229 |
|
|
3,698 |
|
||
|
Prepaid expenses and other assets |
10,839 |
|
|
7,574 |
|
||
|
Discontinued operations, current assets |
— |
|
|
5,555 |
|
||
|
Total current assets |
306,015 |
|
|
250,688 |
|
||
|
Property and equipment, net of accumulated depreciation |
4,534 |
|
|
385 |
|
||
|
Other assets |
8,277 |
|
|
7,188 |
|
||
|
Facility and equipment under lease |
3,842 |
|
|
— |
|
||
|
Discontinued operations, non-current assets |
— |
|
|
132,625 |
|
||
|
Total assets |
$ |
322,668 |
|
|
$ |
390,886 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
||||
|
Current liabilities: |
|
|
|
||||
|
Accounts payable and other accrued liabilities |
$ |
44,455 |
|
|
$ |
69,460 |
|
|
Accrued payroll and benefits |
5,262 |
|
|
9,853 |
|
||
|
Contract liabilities |
7,245 |
|
|
4,850 |
|
||
|
Discontinued operations, current liabilities |
— |
|
|
2,311 |
|
||
|
Total current liabilities |
56,962 |
|
|
86,474 |
|
||
|
Deferred tax liabilities |
— |
|
|
1,469 |
|
||
|
Other long-term liabilities |
10,923 |
|
|
5,650 |
|
||
|
Discontinued operations, non-current liabilities |
— |
|
|
14,031 |
|
||
|
Total liabilities |
67,885 |
|
|
107,624 |
|
||
|
Commitments and contingencies |
|
|
|
||||
|
Stockholders’ equity: |
|
|
|
||||
|
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding |
— |
|
|
— |
|
||
|
Common stock, $0.001 par value; 300,000,000 shares authorized; 112,684,387 and 110,525,141 |
112 |
|
|
110 |
|
||
|
Additional paid-in capital |
905,871 |
|
|
886,740 |
|
||
|
Accumulated other comprehensive loss |
(3,764 |
) |
|
(3,702 |
) |
||
|
Accumulated deficit |
(647,436 |
) |
|
(599,886 |
) |
||
|
Total stockholders’ equity |
254,783 |
|
|
283,262 |
|
||
|
Total liabilities and stockholders’ equity |
$ |
322,668 |
|
|
$ |
390,886 |
|
Non-GAAP Financial Measures (from Continuing Operations)
In this press release, Spectrum reports certain historical results that have not been prepared in accordance with generally accepted accounting principles (GAAP), including non-GAAP selling, general and administrative expenses, non-GAAP research and development expenses, non-GAAP net loss and non-GAAP net loss per share. Non-GAAP financial measures are reconciled to the most directly comparable GAAP financial measures in the tables of this press release and the accompanying footnotes. The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with GAAP. The non-GAAP financial measures presented exclude the items summarized in the below table.
Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the company’s on-going core operating performance. Management uses non-GAAP net income (loss) in its evaluation of the company’s core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that these non-GAAP financial measures are useful to investors in providing greater transparency to the information used by management in its operational decision-making. Management believes that the use of these non-GAAP financial measures also facilitates a comparison of the Company’s underlying operating performance with that of other companies in its industry, which use similar non-GAAP measures to supplement their GAAP results.
The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the company’s business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, other companies, including other companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting their usefulness as a comparative tool. Investors and potential investors are encouraged to review the reconciliation of our non-GAAP financial measures contained within this news release with our GAAP financial results.
|
SPECTRUM PHARMACEUTICALS, INC. Reconciliation of Non-GAAP Adjustments for Condensed Consolidated Statements of Operations (In thousands, expect per share amounts) |
|||||||||||||||||
|
|
|
CONTINUING OPERATIONS ONLY |
|
CONTINUING OPERATIONS ONLY |
|||||||||||||
|
Three Months Ended |
Six Months Ended |
||||||||||||||||
|
June 30, |
June 30, |
||||||||||||||||
|
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|||||||||
|
(1) |
GAAP selling, general and administrative |
$ |
17,230 |
|
|
$ |
16,391 |
|
|
$ |
33,182 |
|
|
$ |
33,007 |
|
|
|
|
Non-GAAP adjustments to SG&A: |
|
|
|
|
|
|
|
|||||||||
|
|
Stock-based compensation expense |
(3,555 |
) |
|
(2,531 |
) |
|
(7,030 |
) |
|
(4,784 |
) |
|||||
|
|
Depreciation expense |
(56 |
) |
|
(61 |
) |
|
(122 |
) |
|
(108 |
) |
|||||
|
|
Lease expense |
— |
|
|
— |
|
|
(129 |
) |
|
— |
|
|||||
|
|
Severance expense |
126 |
|
|
— |
|
|
(1,515 |
) |
|
— |
|
|||||
|
|
Non-GAAP selling, general and administrative |
$ |
13,745 |
|
|
$ |
13,799 |
|
|
$ |
24,386 |
|
|
$ |
28,115 |
|
|
|
(2) |
GAAP research and development |
$ |
16,982 |
|
|
$ |
16,595 |
|
|
$ |
38,868 |
|
|
$ |
29,960 |
|
|
|
|
Non-GAAP adjustments to R&D: |
|
|
|
|
|
|
|
|||||||||
|
|
Stock-based compensation expense |
(1,344 |
) |
|
(650 |
) |
|
(2,227 |
) |
|
(1,281 |
) |
|||||
|
|
Depreciation expense |
(13 |
) |
|
(2 |
) |
|
(15 |
) |
|
(5 |
) |
|||||
|
|
Severance expense |
286 |
|
|
— |
|
|
(260 |
) |
|
— |
|
|||||
|
|
R&D milestones and in-license upfront fees |
(2,751 |
) |
|
(500 |
) |
|
(2,751 |
) |
|
(500 |
) |
|||||
|
|
Non-GAAP research and development |
$ |
13,160 |
|
|
$ |
15,443 |
|
|
$ |
33,615 |
|
|
$ |
28,174 |
|
|
|
(3) |
GAAP net (loss) income from continuing operations |
$ |
(28,783 |
) |
|
$ |
14,894 |
|
|
$ |
(68,603 |
) |
|
$ |
(4,279 |
) |
|
|
|
Non-GAAP adjustments to net (loss) income from continuing operations: |
|
|
|
|
|
|
|
|||||||||
|
|
Adjustments to SG&A and R&D as noted above |
7,307 |
|
|
3,744 |
|
|
14,049 |
|
|
6,678 |
|
|||||
|
|
Adjustments to other (income) expense |
(3,477 |
) |
|
(47,789 |
) |
|
8,428 |
|
|
(57,333 |
) |
|||||
|
|
Adjustments to (benefit) provision for income taxes |
(212 |
) |
|
370 |
|
|
(8,454 |
) |
|
(698 |
) |
|||||
|
|
Non-GAAP net loss from continuing operations |
$ |
(25,165 |
) |
|
$ |
(28,781 |
) |
|
$ |
(54,580 |
) |
|
$ |
(55,632 |
) |
|
|
(4) |
GAAP net (loss) income from continuing operations – per basic share |
$ |
(0.26 |
) |
|
$ |
0.15 |
|
|
$ |
(0.63 |
) |
|
$ |
(0.04 |
) |
|
|
|
GAAP net (loss) income from continuing operations – per diluted share |
$ |
(0.26 |
) |
|
$ |
0.14 |
|
|
$ |
(0.63 |
) |
|
$ |
(0.04 |
) |
|
|
|
Non-GAAP net loss from continuing operations – per basic and diluted share |
$ |
(0.23 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.50 |
) |
|
$ |
(0.55 |
) |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
Weighted average shares outstanding: |
|
|
|
|
|
|
|
|||||||||
|
|
Basic |
110,345,135 |
|
102,597,059 |
|
109,744,405 |
|
101,747,416 |
|||||||||
|
|
Diluted |
110,345,135 |
|
112,617,150 |
|
109,744,405 |
|
101,747,416 |
|||||||||
(1) Non-GAAP selling, general and administrative expenses (from continuing operations): These amounts reflect adjustments to reverse allocated operating expenses for certain non-cash items (including stock-based compensation, depreciation and lease expense), as well as the reversal of non-recurring severance expenses. We believe the resulting non-GAAP SG&A value is reflective of the period-over-period success of our administrative expense control and more indicative of our normalized SG&A expense trends.
(2) Non-GAAP research and development expenses (from continuing operations): These amounts reflect adjustments to reverse allocated operating expenses for certain non-cash items (including stock-based compensation and depreciation), as well as non-recurring severance expenses and R&D milestone achievements and upfront in-license fees that we record to this expense caption. We believe this resulting non-GAAP R&D value is more indicative of our normalized R&D expense trends.
(3) Non-GAAP net loss (from continuing operations): These amounts reflect all non-GAAP adjustments described in (1) through (2) above, plus other non-cash and/or non-recurring items, including: (i) adjustments to reverse the impact of income taxes; (ii) reversal of foreign exchange gains and losses (non-cash); (iii) reversal of debt discount accretion expense (non-cash) for our convertible notes during the prior year period; and (iv) reversal of the mark-to-market adjustment (non-cash) on our equity securities holdings.
(4) Non-GAAP net loss per share (from continuing operations): These amounts reflect all non-GAAP adjustments in (1) through (3) above to present our overall non-GAAP financial results for each period on a per-share basis.
Contacts
Shiv Kapoor
Vice President, Strategic Planning & Investor Relations
702-835-6300
[email protected]